Serum β-synuclein predicts dementia conversion and mortality beyond amyloid-β and phospho-tau.
Serum β-synuclein provided prognostic information largely independent of CSF Aβ42/Aβ40 across all endpoints and of pTau181 for survival outcomes, while sharing substantial prognostic variance beyond CSF biomarkers.